Kits for preventing and treating ebola

Abstract

A kit for reducing the risk of filovirus hemorrhagic fever or a symptom thereof in a mammal host exposed to a filovirus (e.g., Ebola or Zika virus), comprising an effective amount of quercetin-3β-O-D-glucoside (Q3G) or an analogue thereof, or a composition comprising Q3G or analogue thereof and a pharmaceutically acceptable carrier.

1 . A kit for use in the prevention or treatment of a filovirus hemorrhagic disease or a flavivirus disease comprising (i) quercetin-3 β-O-D-glucoside (Q3G) or an analogue thereof, or a composition comprising Q3G or the analogue thereof and a pharmaceutically acceptable carrier; and (ii) (a) another antiviral agent; (iii) instructions to use (i) in the prevention or treatment of a filovirus hemorrhagic disease or a flavivirus disease; or (c) a combination of (a) and (b). 
     
     
         2 . The kit of  claim 1 , comprising between 11 and 25 daily doses of 30 mg to 2 g, or 30 mg to 1 mg, or 30 mg to 800 mg of Q3G or the analogue thereof. 
     
     
         3 . The kit of  claim 1 , wherein (i) is Q3G. 
     
     
         4 . The kit of  claim 1 , wherein the filovirus hemorrhagic fever or symptom thereof is Ebola virus disease (EVD) or a symptom thereof and the filovirus is an ebolavirus. 
     
     
         5 . The kit of  claim 1 , wherein the host is infected by the Zaire ebolavirus (EBOV). 
     
     
         6 . The kit of  claim 1 , wherein the host is infected by the Sudan ebolavirus (SUDV). 
     
     
         7 . The kit of  claim 1 , wherein the host is infected by the Reston ebolavirus (RESTV). 
     
     
         8 . The kit of  claim 1 , wherein Q3G or the analogue thereof, or the composition is for administration by an oral route. 
     
     
         9 . The kit of  claim 1 , wherein Q3G or the analogue thereof, or the composition is for administration by a parenteral route.